An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for Emerging Threat: Melanotan, Repackaging, and Online Sales FDA's Overreach on Compounded Peptides Melanotan II (Tan Jabs): Why They're Not Worth The Risk